Alzheimer's disease (AD) 1 is a neurodegenerative disorder characterized by progressive cognitive impairment. AD is associated with cortical neuronal loss with gliosis, synaptic dysfunction, and widespread senile plaques consisting of amyloid ␤ and neurofibrillary tangles (NFTs) . Substantial evidence has demonstrated that cortical neurons and glial cells undergo apoptotic cell death in AD (1) (2) (3) (4) , and activation of the apoptotic pathways may contribute to the pathogenesis of AD and other neurological diseases (5, 6) .
WW domain-containing oxidoreductase WWOX/FOR/WOX1 is a proapoptotic protein (7) (8) (9) (10) (11) . The wild type WOX1 (46 kDa) possesses two NH 2 -terminal WW domains (containing conserved tryptophan residues), a nuclear localization sequence, and a COOH-terminal short-chain alcohol dehydrogenase/reductase (ADH/SDR) domain. The WW domain sequence is conserved. A mitochondria-targeting region has been identified in the ADH/SDR domain of WOX1, and a portion of cytosolic WOX1 is present in the mitochondria (7) . During apoptosis, mitochondrial WOX1, along with cytochrome c, is released and translocated to the nucleus (7) . Stress stimuli such as anisomycin and UV light stimulate WOX1 phosphorylation at Tyr 33 , leading to the binding of WOX1 with p53 and JNK1 (c-Jun NH 2 -terminal kinase) (10) . Overexpressed WOX1 induces apoptosis synergistically with p53 (7) . p53 apoptosis is abolished by antisense WOX1 (7) or by a dominant negative WOX1 (10) , indicating a functional cooperation between p53 and WOX1.
Human WWOX gene, encoding the WWOX/FOR/WOX1 family proteins, has been mapped to a fragile site on chromosome 16q23.2 (for reviews, see Refs. 8, 9, and 11) . Approximately 50% of loss of heterozygosity of this gene is found in breast, prostate, lung, and esophageal squamous carcinomas. Additionally at least eight aberrant mRNA transcripts have been found in cancer cells (11) . WOX1 is considered to be a candidate tumor suppressor (11) (12) (13) (14) . Nonetheless the protein level of WOX1 is significantly increased in several cancers, raising the question whether WOX1 can act as a tumor suppressor (15) .
The role of WOX1 in regulating the development and function of neural cells is largely unknown. Our recent study demonstrated that WOX1 is likely to play a role in the developing nervous system (16) . WOX1 is differentially expressed during various stages of brain development in mice. Most interestingly, high levels of WOX1 expression are observed in the neural crest-derived structures such as cranial and spinal gan-glia, skin pigment cells, and mesenchyme in the head, indicating a potential role of WOX1 in promoting neuronal differentiation and maturation.
Compared with cognitive normal age-matched controls, we demonstrated here that the protein levels of WOX1, its isoform WOX2 (17) , and Tyr 33 phosphorylation in WOX1 (p-WOX1) (10) were significantly down-regulated in the hippocampi of AD patients. In contrast, phosphorylation of Tau, ERK, and GSK-3␤ and NFT formation were significantly up-regulated in the AD hippocampi. Specifically we determined that Tau phosphorylation at Thr 205 /Thr 212 /Thr 231 and Ser 202 /Ser 422 /Ser 515 / Ser 516 was significantly increased. These phosphorylation sites are regulated by GSK-3␤, cdk5, and ERK (or mitogen-activated protein kinase) (18 -24) . In AD brains, activated GSK-3␤, cdk5, JNK, p38, ERK, and other kinases are known to hyperphosphorylate Tau, leading to the formation of NFTs in degenerative neurons (18 -24) .
To examine whether down-regulation of WOX1 is essential for Tau phosphorylation in AD, we determined that suppression of WOX1 expression by small interfering RNA (siRNA) spontaneously induced phosphorylation of Tau To further establish the underlying mechanism, we showed that WOX1 colocalized with JNK1, GSK-3␤, and Tau in the hippocampal neurons. 17␤-Estradiol (E 2 ), an estrogen, enhanced the binding of WOX1 with phosphorylated Tau. Estrogen protects neuronal cells from apoptosis (25) (26) (27) (28) . As mapped by yeast two-hybrid analysis (7, 10), we determined that the ADH/SDR domain of WOX1 interacted with Tau. How WOX1 regulates Tau phosphorylation and the functional significance of WOX1 down-regulation in AD are discussed.
EXPERIMENTAL PROCEDURES
Cell Lines and Chemicals-Cell lines used in these studies were human neuroblastoma SK-N-SH cells, murine L929 fibroblasts, and monkey kidney COS7 fibroblasts. These cells have been routinely grown in our laboratories according to the instructions of ATCC. E 2 and anisomycin, an activator of JNK1 (10), were from Sigma. SP600125, an inhibitor of JNK1 (29) , was from Biomol. PD-98059, an inhibitor of MEK1/2, was from Calbiochem.
Antibodies-Generation of rabbit antibody against a synthetic peptide, corresponding to amino acids 89 -107 of the NH 2 -terminal murine WOX1, was performed as described previously (7) . It is a pan antibody that interacts with the wild type murine, rat, and human WOX1 and other WOX family proteins possessing an intact NH 2 -terminal WW domain. Antibodies were also generated against the unique COOH termini of human WOX1 (amino acids 397-414, NH 2 -LWALSER-LIQERLGSQSG-COOH) and human WOX2 (also known as FOR1, amino acids 353-363, NH 2 -VSDCLVEGGHF-COOH). Additionally antibody production against a synthetic peptide, NH-CKDGWVY P Y-ANHTEEKT-COOH (where P Y is phosphotyrosine), was performed as described previously (10) .
Additional antibodies used were against the following: 1) human p53, JNK1, Tau, phosphorylated Tau (Ser 515 /Ser 516 ), GSK-3␤, and phosphorylated GSK-3␤ (Tyr 216 ) (Santa Cruz Biotechnologies); 2) human PHFTau with Alzheimer-specific epitope of AT100 (Thr 212 /Ser 214 ) (Pierce); 3) ␤-tubulin (used in the Sze laboratory, Roche Applied Science); 4) ␤-actin (used in the Pugazhenthi laboratory, Roche Applied Science); and 4) ␣-tubulin (used in the Chang laboratory, Accurate Chemicals). A sampler pack of antibodies against Tau was from BIOSOURCE that included a Tau pan antibody, an NFT antibody, and 11 antibodies for site-specific phosphorylation in the human Tau (Thr(P) 181 , Ser(P) 202 , Thr(P) 205 , Thr(P) 212 , Ser(P) 214 , Thr(P) 231 , Ser(P) 262 , Ser(P) 396 , Ser(P) 404 , Ser(P) 409 , and Ser(P) 422 ). (30) .
Immunohistochemistry-The above mentioned hippocampal tissues were formalin-fixed and paraffin-imbedded. The blocks were sectioned (5 m) and mounted on plus slides. The tissues were deparaffinized and hydrated through serial ethanol solutions and finally in distilled water. The hydrated tissue sections were steamed in 10 mM sodium citrate buffer (pH 6.0) for 30 min for antigen retrieval followed by treatment with 1% hydrogen peroxide (10 min) and blocking with 5% horse serum (1 h) at room temperature. The tissue sections were incubated with aliquots of antibodies (1:200 final dilution) against WOX1, WOX2, and p-WOX1, respectively, in Tris-buffered saline (pH 7.4) at 4°C overnight. Aliquots of biotinylated secondary antibodies were then added. Color development was performed using a labeled streptavidin biotin plus horseradish peroxidase kit (Dako). In negative controls, tissue sections were stained with aliquots of prebled rabbit sera. Where indicated, synthetic peptides (100 M) were premixed with the above mentioned antisera (5 min at room temperature) prior to immunostaining.
Immunofluorescence Microscopy-In some experiments, the hippocampal tissues were stained with antibodies against JNK1 (rabbit antibody) and/or Tau (goat antibody) followed by addition of secondary fluorescein isothiocyanate-conjugated anti-rabbit IgG and Texas Redconjugated anti-goat IgG (7) . The nuclei were stained with 4Ј,6-diamidino-2-phenylindole (DAPI, Calbiochem). The slides were examined by fluorescence microscopy as described previously (7) . Where indicated, other antibodies were used in dual immunostaining.
Western Blotting-A 2-or 4-mm Acu-Punch (Acuderm) was used to obtain hippocampal tissues (100 -200 mg) from frozen postmortem brain slabs. The tissues had been stored at Ϫ80°C and then warmed to Ϫ20°C overnight prior to sampling. These samples were Dounce-extracted in the presence of a mixture of protease inhibitors (Sigma) and then centrifuged at 10,000 rpm for 10 min to remove debris as described previously (31) . The samples (50 g/lane) were quantified by the Bradford method (Bio-Rad) and subjected to SDS-PAGE, electroblotting, and Western blotting as described previously (31) . Scanning and quantification were performed using BioRad Fluor-S TM MultiImager and Quantity One software. The extent of protein expression was expressed as relative OD as determined by comparing the density and area of an immunoreactive band in each lane with those of control lanes in the same blot. The data were assessed by Student's t test and Spearman correlation procedure.
Co-immunoprecipitation-Where indicated, L929 or other cells treated with or without E 2 were extracted using a cytoplasmic and nuclear extraction kit (Pierce) (7, 10) . These protein preparations (ϳ1 mg of protein) were quantified and co-immunoprecipitated (7, 10) using specific antibodies against p-WOX1 or GSK-3␤.
Mammalian Expression Constructs-Murine GFP-WOX1 (in pEGFP-C1, Clontech) was made as described previously (7, 10) . The coding sequence of the ADH/SDR domain in WOX1, designated GFP-WOX1adh, was also constructed in pEGFP-C1. COS7 or the indicated cells were electroporated with these cDNA constructs or the "empty" pEGFP-C1 vector as controls. Protein expression was examined by fluorescence microscopy and Western blotting (7, 10) . Alternatively liposome-based Fu-GENE 6 (Roche Applied Science) or GeneFector (Venn Nova) was used for transferring cDNA constructs into cells (7, 10) .
Cytoplasmic Yeast Two-hybrid Analysis-Ras rescue-based yeast two-hybrid analysis (CytoTrap, Stratagene) was performed as described previously (7, 10) . Briefly binding of a cytosolic Sos-tagged bait protein to a cell membrane-anchored target protein (tagged with a myristoylation signal) activates the Ras signaling pathway in yeast. This activation allows mutant yeast cdc25H to grow in 37°C using a selective agarose plate containing galactose. Without binding, yeast cells fail to grow at 37°C. Constructs (in pSos vector) used as baits were as follows: 1) a murine full-length WOX1, 2) an NH 2 -terminal WW domain area of WOX1, 3) a COOH-terminal ADH/SDR domain area of WOX1, and 4) a Y33R mutant in the WW domain area (for the above constructs as baits) (7, 10) . For target, a construct for human Tau, with three repeats of a microtubule-binding domain (GenBank TM accession number BC000558), was made in pMyr vector. Additional constructs for the binding experiments were human p53 (in pMyr) and MafB (in both pMyr and pSos) (7).
siRNA-targeting WOX1-A retroviral siRNA expression construct for targeting human WOX1 was made (in pSupressorRetro) using a GeneSuppressor construction kit from Imgenex. The synthetic primers (MWG Biotech) for making the expression construct were as follows: 1) forward, 5Ј-TCGAGCCAAGTCCATGCAACAGGGGAGTACTGCCCTG-TTGCATGGACTTT, and 2) reverse, 5Ј-CTAGAAAAACCAAGTCCATG-CACAGGGCAGTACTCCCCTGTTGCATGGACTTGGC. The resulting siRNA targets a sequence at the 3Ј end of WOX1 mRNA. An empty vector was used as a control. Production of retrovirus and transfection to target cells were performed according to the manufacturer's instructions. A similar construct was made using a mammalian expression plasmid, pSuppressorNeo, from Imgenex. Also, a negative control vector with a scrambled sequence was from Imgenex.
In addition, we selected a conserved sequence region at the WW domain of WOX1 for siRNA targeting. This sequence is identical in human, mouse, and zebrafish. Synthetic primers for making the WOX1si construct (in pSuppressorNeo) were as follows: forward, 5Ј-TCG-AGCCAAGTCCATGCACAGGGGAGTACTGCCCTGTTGCATGGACT-TGGTTTTT, and reverse, 5Ј-CTAGAAAAACCAAGTCCATGCACAGG-GCAGTACTCCCCTGTTGCATGGACTTGGC. Where indicated, L929 and SK-N-SH cells were transfected with these constructs by electroporation. Stable transfectants were selected using G418 (300 g/ml) during 2-3 weeks in culture (7, 10) .
RESULTS

Down-regulation of WOX1, p-WOX1, and WOX2 in the Hippocampal Neurons and Extracts of AD Brains-As determined
by immunohistochemistry, WOX1 is present mainly in the perinuclear areas of both healthy and degenerative neurons from an AD hippocampus (Fig. 1A) . Degenerative neurons possess cytoplasmic NFTs and/or granulovacuolar degeneration (Fig.  1A) . Compared with healthy neurons, these degenerative neurons have reduced levels of WOX1. Similarly dystrophic neuritic plaques, an important diagnostic feature for AD, were weakly immunoreactive to WOX1 antibodies (Fig. 1A) .
Compared with normal controls, down-regulation of WOX1 and is also present in small neuron (arrowhead) and astrocytic glial cell (solid arrow) (right panel). Immunostaining was performed using antibodies against a conserved segment in the NH 2 terminus of WOX1 (7). B, WOX1 expression is down-regulated in the neurons of AD hippocampi compared with normal controls (a representative set from five immunostains; amplification, 200ϫ). Antiserum against the unique COOH terminus of human WOX1 was used in the immunohistochemistry (see "Experimental Procedures"). This newly produced antiserum interacted with the full-length 46-kDa WOX1 in the extract (50 g) of a normal human brain. C, our newly generated antibodies interacted with the 41-kDa WOX2 in the extract (50 g) of a normal human brain. Reduced immunoreactivity of WOX2 was found in the neurons of AD brains compared with those cells in control brains (amplification, 200ϫ). Ab, antibody.
was observed in the hippocampal neurons in AD (Fig. 1B) . The results were observed using antibodies against the unique COOH terminus of human WOX1 (Fig. 1B) . The full-length WOX1 (46 kDa) is the major species found in tissues and cultured cells compared with other members of the WWOX/ FOR/WOX1 protein family (7, 11) . Similar results were also obtained using our previously developed antibodies against the NH 2 terminus of WOX1 (7) (see Supplemental Figs. 1-3 ).
In parallel with the above results, the level of a WOX1 isoform, WOX2 (41 kDa), was relatively higher in healthy neurons than that in the AD (Fig. 1C) . The specificity of anti-WOX2 antibodies is shown in Western blotting using a control brain extract (Fig. 1C) .
Although WOX1 is phosphorylated at Tyr 33 during stress and apoptotic responses (10), a portion of endogenous WOX1 is indeed Tyr 33 -phosphorylated in numerous cultured cell lines, brains, and other organs. 2 Significant reduction of Tyr 33 phosphorylation in WOX1 was also observed in the hippocampal neurons of AD brains compared with normal controls (see Supplemental Figs. 1-3) . In appropriate controls, tissue sections were stained with prebled rabbit sera or preblocked with specific synthetic peptides and shown to be negative for immunoreactivity (data not shown).
We confirmed the validity of the above observations by determining the expression of WOX1 and its isoforms in the extracts of AD and control hippocampi. Shown in Fig. 2 are representative immunoblots of WOX1, p-WOX1, WOX2, and ␤-tubulin from the extracts of AD and control hippocampi. The results demonstrate significant down-regulation of WOX1, p-WOX1, and WOX2 in the AD brain extracts compared with age-matched controls (ϳ32 Ϯ 5% reduction, Fig. 2) .
Knock-down of WOX1 Expression Induces Tau Phosphorylation at Thr
212 /Thr 231 and NFT Formation-To determine the potential functional significance regarding WOX1 down-regulation in the AD hippocampi, we knocked down WOX1 expression by siRNA (WOX1si, constructed in pSuppressorNeo plasmid) in human SK-N-SH neuroblastoma cells. The designed siRNA targeted the unique 3Ј end sequence of human WOX1 mRNA. Transient expression of WOXsi in SK-N-SH cells suppressed WOX1 protein expression by greater than 50% compared with control cells expressing a scrambled siRNA (Fig.  3A) . In these WOX1si-expressing cells, phosphorylation of Tau at Thr 231 (55 kDa but not 100 kDa) and Thr 212 (120 kDa) was significantly increased (Fig. 3A) . Phosphorylation of these sites is GSK-3␤-dependent. Also WOX1si increased NFT formation in SK-N-SH cells as determined by cell immunostaining and Western blotting (Fig. 3B) . The soluble fraction of NFTs (55, 75, and 120 kDa) was shown in Western blotting. The Thr 212 -phosphorylated Tau (120 kDa) in SK-N-SH cells corresponds to the soluble 120-kDa NFTs, suggesting that Thr 212 is phosphorylated when Tau is polymerized to this size.
In parallel, Tau phosphorylation at Thr 231 and Thr 212 was also significantly increased in the AD hippocampi (Fig. 3C) . Activation of JNK1 by anisomycin further increased phosphorylation of Tau at Thr 231 and Thr 212 in scrambled siRNA-and WOX1si-expressing cells (Fig. 3A) . These observations suggest that, under stress conditions, JNK1 is able to phosphorylate Tau at Thr 231 and Thr 212 . Conserved phosphorylation sites are found in Tau isoforms from 35 to 75 kDa. Tau possesses three repeats of a microtubule-binding domain (35-kDa Tau) or three to four repeats (Ͼ35-kDa Tau) (23, 32) . Phosphorylation of these sites has been found in PHF-Tau or tangled Tau (33) (34) (35) . Compared with age-matched controls, a panel of Tau phosphorylation at various threonine and serine sites in the AD hippocampi is shown in Supplemental Figs. 1-3 .
Retroviral Expression of WOX1si-The above observations were further verified using retroviral expression of WOX1si (targeting the same 3Ј end region of WOX1 mRNA as indicated above). Cells were transfected with the WOX1si or an empty retrovirus and cultured for 48 h. Suppression of WOX1 expression in SK-N-SH cells was observed (Fig. 4A) .
Suppression of WOX1 by siRNA increased phosphorylation of Tau at Ser 515 /Ser 516 and Thr 212 /Ser 214 (by ϳ100%), and this positively correlates with enhanced phosphorylation of GSK-3␤ and ERK (Fig. 4A) . As determined by co-immunoprecipitation, there was an increased binding of phosphorylated GSK-3␤ with phospho-Tau in these WOX1 knock-down cells (Fig. 4B) . In comparison, Tau phosphorylation at Ser 515 /Ser 516 in control and AD hippocampi is shown (Fig. 4C) .
Phosphorylation of Ser 515 /Ser 516 , Thr 212 , and Ser 214 in Tau is mediated by ERK, GSK-3␤, and protein kinase A, respectively. Phosphorylation of Thr 212 /Ser 214 was determined using PHFTau antibodies (AT100). The Alzheimer-specific AT100 epitope in Tau is present only in its PHF conformation (32) (33) (34) (35) . Nonetheless little or no phosphorylation of Ser 214 was observed in the hippocampi and SK-N-SH cells (data not shown) as determined using specific anti-Ser(P) 214 has shown that phosphorylation of Thr 212 may affect the subsequent phosphorylation of Ser 214 (36) . Also Ser 214 was not phosphorylated in a P301S Tau transgenic mouse model (37) . E 2 protects SK-N-SH cells from apoptosis (25) . The above SK-N-SH cells were treated with E 2 for 30 min. E 2 had no apparent effect on the phosphorylation of Tau in both control and WOX1si-expressing SK-N-SH cells during a short term treatment (Fig. 4A) , although it can effectively activate WOX1 in various types of cancer cells. 2 
Inhibition of Tau Phosphorylation and NFT Formation by PD-98059 and SP600125 in WOX1si
-expressing Cells-To further substantiate our observations, we selected a sequence in the WW domain area for siRNA targeting. We established stable transfectants of L929 and SK-N-SH cells expressing the constructed WOX1si (in pSuppressorNeo) or a scrambled siRNA. As expected, knock-down of WOX1 expression significantly induced NFT formation in L929 cells (Fig. 5A) . The increased NFT formation was inhibited by exposure of these cells to an MEK1/2 inhibitor, PD-98059, and a JNK inhibitor, SP600125, for 1 h (Fig.  5A ). These chemicals also reduced the phosphorylation of Tau at Ser 515 /Ser 516 (Fig. 5B , data not shown for PD-98059). These observations suggest that both ERK and JNK1 participate in the formation of NFTs in these WOX1si-expressing cells. Similarly the above events were also observed in WOX1si-expressing SK-N-SH cells (data not shown).
Ectopic or Endogenous WOX1 Colocalizes with Tau, JNK1, and GSK-3␤ in Neurons and
Cultured Cells-By fluorescence microscopy, endogenous p-WOX1 was shown to colocalize with phospho-JNK1 (p-JNK1) and Ser(P) 515 /Ser(P) 516 -Tau in hippocampal neurons from either AD or age-matched control brains (Fig. 6A, top two panels) . Similar results were observed by examining the colocalization of p-WOX1 with phospho-GSK-3␤ or p-JNK1 with Ser(P) 515 /Ser(P) 516 -Tau (data not shown). Some neurons in the AD brains possessed colocalized p-WOX1 with Ser(P) 515 /Ser(P) 516 -Tau in the NFTs (Fig. 6A,  bottom panel) . Together these observations suggest that WOX1 physically interacts with both JNK1 and Tau in vivo.
JNK1 physically interacts with WOX1 and blocks WOX1-mediated apoptosis (10) . GSK-3␤, cdk5, JNK, p38, ERK1/2, and other kinases phosphorylate Tau in AD (18 -24) . Ectopic GFP-WOX1 was shown to colocalize with endogenous p-JNK1 and Ser(P) 515 /Ser(P) 516 -Tau in COS7 fibroblasts (Fig. 6B) . In controls, GFP alone could not colocalize with the endogenous JNK1 and Tau (Fig. 6B, data not shown for JNK1 and Thr 212 /Ser 214 ) in the cytoplasm, and E 2 increased the binding interaction (Fig. 7A) . WOX1 also bound Tau with phosphorylation at Thr 231 (data not shown). Compared with SK-N-SH cells, L929 cells were more responsive to E 2 -mediated phosphorylation of WOX1 and Tau. E 2 also increased the binding of WOX1 with 45-and 55-kDa Tau in SK-N-SH cells (data not shown). Our precipitating antibodies bound p-WOX1, and this protein was also recognized by the pan antibodies against the NH 2 terminus of WOX1 (Fig. 7A) . Similarly E 2 increased the binding of GSK-3␤ with Tau in L929 cells (Fig. 7B) .
The COOH-terminal ADH/SDR Domain of WOX1 Physically Interacts with Tau-We mapped the domain of WOX1 that interacts with Tau. As determined by a Ras rescue-based yeast two-hybrid analysis in the cytoplasm (7, 10) , the full-length murine WOX1 interacted with Tau in yeast (Fig. 8) . This human TAU clone (GenBank TM accession number BC000558) possesses three repeats of the microtubule-binding domain. However, the NH 2 -terminal WW domains alone could not interact with Tau (Fig. 8) . Failure of the WW domains binding with Tau was not due to its Tyr 33 phosphorylation. Alteration of Tyr 33 to Arg 33 could not induce binding of the WW domains with Tau. The ADH/SDR domain alone physically interacted with Tau. Thus, these observations indicate that the COOHterminal ADH/SDR domain of WOX1 is responsible for interacting with Tau.
In positive controls, there were binding interactions of p53/ WOX1 (7, 10) and MafB self-binding interaction (Fig. 8) . In negative controls, no binding interactions were observed for empty vectors (Fig. 8) .
DISCUSSION
In this study, we demonstrated that WOX1, p-WOX1, and WOX2 were down-regulated in the AD hippocampi. This downregulation correlates negatively with significant increases in phosphorylation of Tau (at Thr  212 We generated specific antibodies against the COOH-terminal amino acid sequences of human WOX1 and WOX2 and the NH 2 terminus of murine WOX1 (7). The antibodies recognized expected protein bands of 46-kDa WOX1 and 41-kDa WOX2 in the human brain extracts. The WOX1 antibodies are expected to interact with a truncated 26-kDa WWOXv4 (according to GenBank TM nomenclature; for a review, see Ref. 11). However, we could not identify this protein in the brains. The COOH-terminal amino acid sequence of WOX2 is unique, and the antibodies generated did not interact with other WWOX/FOR/WOX1 family proteins. By using these antibodies in Western blotting and immunohistochemistry, we convincingly showed the significant down-regulation of WOX1 and WOX2 expression in the AD hippocampi as compared with age-matched controls. In addition, we determined that p-WOX1 was significantly down-regulated in the AD hippocampi. Functional significance of this down-regulation is unknown. WOX1 activation involves Tyr 33 phosphorylation and subsequent nuclear translocation (10, 11) . Ectopic WOX1 induces apoptosis in the nuclear level (7, 10) . Whether endogenously activated WOX1 initiates apoptosis in the nucleus is unknown. However, we believe that during neuronal degeneration, WOX1 undergoes Tyr 33 phosphorylation and nuclear translocation and participates in the apoptosis of neuronal cells. The notion is supported by 1-methyl-4-phenylpyridium intoxication of striatum, which shows a rapid WOX1 activation via Tyr 33 phosphorylation followed by nuclear translocation and colocaliza- (7, 10) . In positive controls, there were binding interactions of p53/WOX1 (7) and MafB self-binding interaction as revealed by the growth of mutant cdc25H yeast at 37°C using a selective galactose-agarose plate. In negative controls, no binding interactions were observed for empty vectors. The full-length murine WOX1 interacted with human Tau via its COOH-terminal ADH/SDR but not NH 2 tion with nuclear p53 in damaged neurons. 3 Presumably, reduction of Tyr 33 phosphorylation in WOX1 indicates a postactivation stage of WOX1 in degenerated neurons.
NFT and neuron numbers, but not amyloid load, are critical in predicting cognitive status in Alzheimer's disease (38) . NFTs are present mostly in the CA1, entorhinal cortex, and area 9 (38 -42) . Neurons in CA4 and CA3 areas are less affected in AD patients, while neuronal loss, in association with NFTs and granulovacuolar degeneration, is found mostly in the CA2, CA1, and the entorhinal regions (38 -42) . The immunoreactivity of WOX1 and WOX2 appears to be maximally expressed in the neurons of CA4 and CA3 regions but is progressively reduced in the neurons of CA2, CA1, and entorhinal cortex of both control and AD hippocampi (see Supplemental Figs. 1-3) . That is, an increased NFT formation in a specific hippocampal region correlates negatively with the levels of WOX1 and WOX2.
There are six isoforms of Tau in human brains, and the microtubule-binding repeat region plays an important role in Tau polymerization (for a review, see Ref. 17) . However, regions outside the microtubule-binding repeat, such as exons 2 and 3 and the COOH-terminal tail, can greatly influence its polymerization. Recently the NH 2 terminus of Tau has also been shown to regulate tangle formation (43) . Abnormal polymerization of mutant Tau into insoluble filaments contributes to neurodegeneration in AD (44 -46) . Numerous enzymes are involved in Tau hyperphosphorylation, and cdk5 and GSK-3␤ appear to play a dominant role in Tau pathology (18 -24) . Aberrant cdk5 activation by p25 induces neurodegeneration and tangle formation (47) . Nonetheless brain levels of cdk5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles (48) .
We have exhaustively examined Tau phosphorylation in the AD hippocampi versus age-matched normal controls using a panel of specific antibodies against phospho-Tau (see Supplemental Figs. 1-3 (32-35) , was not observed both in the AD hippocampi and in the WOXsi-expressing SK-N-SH cells. These data suggest that, when Tau is in a specific conformation, certain sites can readily undergo phosphorylation, whereas other sites resist phosphorylation. It has been determined that phosphorylation of Thr 212 may affect the subsequent phosphorylation of Ser 214 (36) . Indeed Ser 214 was not phosphorylated in a P301S Tau transgenic model (37) .
Stress-induced JNK activation is involved in the Tau hyperphosphorylation and pathology of AD (23, 49) . Our Heat shock also induces Tau hyperphosphorylation. It is of interest to note that molecular chaperones or heat shock proteins Hsp70, Hsp90, and Hsp27 reduce phosphorylation but promote solubility and binding of Tau to microtubules, thereby increasing cell survival (50, 51) . Also CHIP (carboxyl terminus of the Hsc70-interacting protein) and Hsp70 regulate Tau ubiquitination, degradation, and aggregation and enhance cell survival (52, 53) .
Phosphorylated ERK, p38, JNK1, and calmodulin kinase II are differentially expressed in Tau deposits in neurons and glial cells in tauopathies (18, 19) . We determined that WOX1 physically interacted with Tau, JNK1, and GSK-3␤ in the extracts of rat brains and cultured cells (data not shown for rat brains). Thus, WOX1 is likely to prevent phosphorylation of Tau by JNK1, GSK-3␤, and other enzymes in vivo. This notion is supported by the observation that WOX1 bound Tau via its COOH-terminal ADH/SDR domain. Our preliminary data show that ectopic expression of this domain suppressed E 2 -induced Tau phosphorylation at Thr 212 /Ser 214 and Ser 515 / Ser 516 . The ADH/SDR domain possesses a conserved NSYK motif that may bind substrates such as E 2 and other sex hormones (11) . Estrogen is protective against neuronal death (25) (26) (27) (28) . E 2 induces cytosolic Tau expression during 24-h treatment of human SH-SY5Y neuroblastoma cells (56) , induces differentiation of a neuronal cell line (57), but cannot change Tau expression in rat brains (58) . In this study, we determined that during a short term treatment for less than 1 h, E 2 enhanced the binding of WOX1 with phosphorylated Tau at Thr 212 /Ser 214 and Ser 515 /Ser 516 and GSK-3␤ with Tau and WOX1 in L929 cells. However, E 2 may increase Tau phosphorylation during treatment for longer than 1 h (data not shown). Accordingly, WOX1 is likely to prevent further enzyme-mediated Tau phosphorylation. The functional role of WOX1 in preventing E 2 -increased Tau phosphorylation in vivo remains to be established.
Finally, both WOX1 and prolyl isomerase PIN1 interact with phosphorylated or activated p53 (on (Ser/Thr)-Pro motifs) during DNA damage (for a review, see Ref. 11) . PIN1 possesses an NH 2 -terminal WW domain and a COOH-terminal isomerase domain. The WW domain in PIN1 binds to phosphorylated p53 on the (Ser/Thr)-Pro motifs and the polyproline region. This type of binding is similar to that of the WOX1 interaction with p53 (7, 11) . PIN1 binds (via its WW domain) and colocalizes with Thr 231 -phosphorylated Tau in Alzheimer's disease and other tauopathies (42, 54, 59 ). In contrast, WOX1 binds Tau through its ADH/SDR domain. Like WOX1, PIN1 expression is inversely correlated with predicted neuronal vulnerability and actual neurofibrillary degeneration in Alzheimer's disease (55) . A transgenic PIN1 mouse model shows that PIN1 is able to protect against age-dependent neurodegeneration (55) . In summary, our study demonstrated that WOX1 binds Tau via its ADH/SDR domain and is likely to prevent E 2 -and enzyme-mediated Tau phosphorylation in vivo. Down-regulation of WOX1 in the AD neurons induces Tau hyperphosphorylation and subsequent NFT formation, indicating a protective role of WOX1 in neurodegeneration.
